GlassScriptPhysician profile
David J Monroe
NPI 1194710749
$5,276.33
in general payments reported to CMS, 2019-2025
17 companies · $1,766 in 2025
The $1,766 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $46.82 · 2021: $255 · 2022: $667 · 2023: $926 · 2024: $1,395 · 2025: $1,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051 · Education: $35.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.91 |
| Education | $35.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,447.96 | 2023-2025 | Miebo, Xiidra, Infuse |
| Tarsus Pharmaceuticals, INC. | $1,128.95 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $636.22 | 2021-2025 | Acuvue |
| Oyster Point Pharma, INC. | $520.64 | 2022-2025 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $449.76 | 2019-2025 | Precision7, Total30, Tryptyr |
| Sun Pharmaceutical Industries INC. | $282.01 | 2019-2025 | Cequa |
| Coopervision INC. | $192.74 | 2022-2024 | Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $186.91 | 2021-2023 | |
| Allergan, INC. | $162.42 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $89.52 | 2019-2021 | |
| Biotissue Holdings INC. | $49.89 | 2019-2020 | |
| Dompe US, INC. | $37.26 | 2022 | |
| Harrow Eye, LLC | $24.72 | 2024 | Vevye |
| Vyera Pharmaceuticals, LLC | $20.89 | 2019 | |
| Aerie Pharmaceuticals, INC. | $19.77 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $14.27 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Monroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.